Shabet Rose Sharon

CIK 000171139321 companiesSTAMFORD, CT

SEC Profile

Transactions

Companies

Filings

CIK

0001711393

Recent Transactions

50 trades

Sale
Inhibrx Biosciences, Inc.$INBX
Common Stock
2025-10-07$32.25/sh−308,643→ 1,267,823 total
Sale
Inhibrx Biosciences, Inc.$INBX
Common Stock
2025-10-07$32.25/sh−25,042→ 102,864 total
Sale
Inhibrx Biosciences, Inc.$INBX
Common Stock
2025-10-07$32.25/sh−16,315→ 67,018 total
Sale
BridgeBio Pharma, Inc.$BBIO
Common Stock
2025-06-27$44.00/sh−3,500,000→ 18,555,375 total
Sale
BridgeBio Pharma, Inc.$BBIO
Common Stock
2025-01-31$34.90/sh−3,065,616→ 22,055,375 total
Sale
APi Group Corp$APG
Common Stock
2024-06-17$38.15/sh−1,912,750→ 0 total
Sale
APi Group Corp$APG
Common Stock
2024-06-17$38.15/sh−39,032→ 0 total
Sale
APi Group Corp$APG
Common Stock
2024-06-17$38.15/sh−39,032→ 0 total
Sale
APi Group Corp$APG
Common Stock
2024-06-17$38.15/sh−1,912,750→ 0 total
Other
Inhibrx, Inc.
Warrants (right to buy)
2024-05-30$30.00/sh−1,038,765→ 0 total
Other
Inhibrx, Inc.
Common Stock
2024-05-30$30.00/sh−6,305,866→ 0 total
Other
Inhibrx, Inc.
Common Stock
2024-05-30$30.00/sh−333,333→ 0 total
Other
Inhibrx, Inc.
Common Stock
2024-05-30$30.00/sh−511,627→ 0 total
Sale
APi Group Corp$APG
Common Stock
2024-03-05$34.25/sh−60,772→ 39,032 total
Sale
APi Group Corp$APG
Common Stock
2024-03-05$34.25/sh−2,977,845→ 1,912,750 total
Sale
APi Group Corp$APG
Common Stock
2024-03-05$34.25/sh−2,977,845→ 1,912,750 total
Sale
APi Group Corp$APG
Common Stock
2024-03-05$34.25/sh−60,772→ 39,032 total
Conversion
APi Group Corp$APG
Common Stock
2024-02-28$24.60/sh+8,036,862→ 8,874,334 total
Conversion
APi Group Corp$APG
5.5% Series B Perpetual Convertible Preferred Stock
2024-02-28−4,000→ 0 total
Conversion
APi Group Corp$APG
Common Stock
2024-02-28$24.60/sh+164,016→ 181,104 total
Other
APi Group Corp$APG
Common Stock
2024-02-28$36.90/sh−3,983,739→ 4,890,595 total
Other
APi Group Corp$APG
Common Stock
2024-02-28$36.90/sh−81,300→ 99,804 total
Conversion
APi Group Corp$APG
Common Stock
2024-02-28$24.60/sh+164,016→ 181,104 total
Conversion
APi Group Corp$APG
5.5% Series B Perpetual Convertible Preferred Stock
2024-02-28−196,000→ 0 total
Conversion
APi Group Corp$APG
Common Stock
2024-02-28$24.60/sh+8,036,862→ 8,874,334 total
Other
APi Group Corp$APG
Common Stock
2024-02-28$36.90/sh−81,300→ 99,804 total
Conversion
APi Group Corp$APG
5.5% Series B Perpetual Convertible Preferred Stock
2024-02-28−196,000→ 0 total
Conversion
APi Group Corp$APG
5.5% Series B Perpetual Convertible Preferred Stock
2024-02-28−4,000→ 0 total
Other
APi Group Corp$APG
Common Stock
2024-02-28$36.90/sh−3,983,739→ 4,890,595 total
Other
RayzeBio, Inc.
Common Stock
2024-02-26−1,743,556→ 0 total
Other
RayzeBio, Inc.
Common Stock
2024-02-26−4,899,144→ 0 total
Other
RayzeBio, Inc.
Common Stock
2024-02-26−1,743,556→ 0 total
Other
RayzeBio, Inc.
Common Stock
2024-02-26−4,899,144→ 0 total
Sale
4D Molecular Therapeutics, Inc.$FDMT
Common Stock
2024-01-04$19.53/sh−540,000→ 4,247,914 total
Sale
APi Group Corp$APG
Common Stock
2024-01-02$31.30/sh−195,200→ 837,472 total
Sale
APi Group Corp$APG
Common Stock
2024-01-02$31.30/sh−6,300,817→ 27,032,516 total
Sale
APi Group Corp$APG
Common Stock
2024-01-02$31.30/sh−195,200→ 837,472 total
Sale
APi Group Corp$APG
Common Stock
2024-01-02$31.30/sh−3,983→ 17,088 total
Sale
APi Group Corp$APG
Common Stock
2024-01-02$31.30/sh−6,300,817→ 27,032,516 total
Sale
APi Group Corp$APG
Common Stock
2024-01-02$31.30/sh−3,983→ 17,088 total
Conversion
RayzeBio, Inc.
Series D Convertible Preferred Stock
2023-09-19−1,285,223→ 0 total
Conversion
RayzeBio, Inc.
Series C Convertible Preferred Stock
2023-09-19−432,254→ 0 total
Conversion
RayzeBio, Inc.
Series B Convertible Preferred Stock
2023-09-19−864,509→ 0 total
Purchase
RayzeBio, Inc.
Common Stock
2023-09-19$18.00/sh+930,556→ 4,899,144 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+864,509→ 864,509 total
Purchase
RayzeBio, Inc.
Common Stock
2023-09-19$18.00/sh+458,333→ 1,743,556 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+2,609,392→ 3,968,588 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+494,687→ 1,359,196 total
Conversion
RayzeBio, Inc.
Series C Convertible Preferred Stock
2023-09-19−432,254→ 0 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+1,285,223→ 1,285,223 total

Recent Filings

Address

600 WASHINGTON BLVD. FLOOR 11

STAMFORD, CT, 06901

View on SEC.gov